EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Immunology of DLBCL

Taishi Takahara, Shigeo Nakamura, Toyonori Tsuzuki iD, Akira Satou

Cancers · 29.01.2023 · 15 (3) · 835

DOI: 10.3390/cancers15030835 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.01.2023. Verfasst von Taishi Takahara und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute 480-1195, Japan. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and is the most common type of malignant lymphoid neoplasm. While some DLBCLs exhibit strong cell-autonomous survival and proliferation activity, others depend on interactions with non-malignant cells for their survival and proliferation. Recent next-generation sequencing studies have linked these interactions with the molecular classification of DLBCL. For example, germinal center B-cell-like DLBCL tends to show strong associations with follicular T cells and epigenetic regulation of immune recognition molecules, whereas activated B-cell-like DLBCL shows frequent genetic aberrations affecting the class I major histocompatibility complex. Single-cell technologies have also provided detailed information about cell–cell interactions and the cell composition of the microenvironment of DLBCL. Aging-related immunological deterioration, i.e., immunosenescence, also plays an important role in DLBCL pathogenesis, especially in Epstein-Barr virus-positive DLBCL. Moreover, DLBCL in “immune-privileged sites”—where multiple immune-modulating mechanisms exist—shows unique biological features, including frequent down-regulation of immune recognition molecules and an immune-tolerogenic tumor microenvironment. These advances in understanding the immunology of DLBCL may contribute to the development of novel therapies targeting immune systems.

Schlagwörter

Stichwörter der Autor:innen

DLBCLimmune escapeimmune-privileged siteimmunosenescence

Autor:innen und Institutionen

  • Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute 480-1195, Japan.
  • Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya 466-8550, Japan.

ORCID-Profile: Toyonori Tsuzuki

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Takahara, T., Nakamura, S., Tsuzuki, T., & Satou, A. (2023). The Immunology of DLBCL. Cancers, 15(3), 835. https://doi.org/10.3390/cancers15030835

Vancouver

Takahara T, Nakamura S, Tsuzuki T, Satou A. The Immunology of DLBCL. Cancers. 2023;15(3):835. doi:10.3390/cancers15030835

BibTeX
@article{Takahara2023,
  author = {Takahara, Taishi and Nakamura, Shigeo and Tsuzuki, Toyonori and Satou, Akira},
  title = {The Immunology of DLBCL},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {3},
  pages = {835},
  doi = {10.3390/cancers15030835}
}
Kostenlos starten →